Abstract
Background
The
Coronavirus
Disease
of
2019
(COVID-19)
pandemic
motivated
research
efforts
to
address
this
catastrophe
from
the
beginning
2020
present.
year
2021
is
coming
an
end,
and
several
developments
in
pharmacotherapy
for
COVID-19
have
occurred.
In
terms
antiviral
therapy,
monoclonal
antibody
combinations
become
one
type
immunotherapy.
Remdesivir
favipiravir
are
two
medications
typically
used
treat
COVID-19.
Paxlovid
(nirmatrelvir
plus
ritonavir)
molnupiravir
other
agents
purpose
study
was
compare
effects
antibodies
(casirivimab
imdevimab),
remdesivir,
on
swab
results
hospitalized
patients
with
at
discharge.
Methods
This
a
phase
IV
non-randomized
controlled
trial
(<
300
as
sample
size)
no
comparison
placebo.
study,
265
confirmed
by
polymerase
chain
reaction
(PCR)
indications
medication
were
into
three
groups
ratio
(1:2:2):
REGN3048-3051
(group
A),
remdesivir
B),
C).
A
nonrandomized
single-blind
design
used.
study's
provided
Hospital
Mansoura
University.
Following
ethical
approval,
conducted
approximately
6
months.
Results
Compared
favipiravir,
casirivimab
imdevimab
cause
less
hepatotoxicity,
renal
impairment,
more
negative
tested
antivirals
also
had
significant
adverse
effects.
All
considered
safe
based
these
findings.
Conclusion
result
better
clinical
outcomes.
toxicity.
Trial
registration
:
Clinicaltrials.gov,
NCT05502081,
16/08/2022.
Infezioni in Medicina,
Год журнала:
2021,
Номер
29(3), С. 312 - 327
Опубликована: Сен. 1, 2021
severe
acute
respiratory
syndrome
coronavirus-2
(SARS-CoV-2)
infection
has
exploded
and
led
to
a
global
crisis.Currently,
the
case
numbers
topped
200
million,
toll
of
dead
exceeded
4
million
around
world.The
pathogenesis
coronavirus
disease
2019
(COVID-19)
is
driven
by
two
processes.During
first
stage
that
lasts
5-7
days,
replication
SARS-CoV-2
occurs.In
second
stage,
may
progress
due
an
exaggerated
inflammatory
response
leading
tissue
damage.Therefore,
it
anticipated
antiviral
agents
would
be
effective
during
early
phase
disease,
while
immunomodulator
are
likely
more
beneficial
in
COVID-19.This
basic
concept
development
explore
several
for
treatment
COVID-19.Currently,
remdesivir
only
available
Food
Drug
Administration-approved
agent
COVID-19.However,
some
other
have
been
approved
various
mechanisms,
including
Emergency
Use
Authorizations,
Investigational
New
applications,
compassionate
use
SUMMARY
or
expanded
access
programs.In
addition,
variety
repurposed
were
indications
being
investigated
CO-VID-19
clinical
trials.A
myriad
publications
randomized
controlled
trials
(RCTs)
emerging
continuously
accessible
as
peer-reviewed,
pre-print
press
release
formats.Considering
critical
importance
RCTs
generating
evidence
providing
further
guidance
on
COVID-19
treatment,
we
herein
reviewed
meta-analyses.The
discussion
includes
(hydroxychloroquine,
lopinavir/ritonavir,
remdesivir,
favipiravir
ivermectin)
and,
immunomodulatory
drugs
(corticosteroids,
tocilizumab,
baricitinib,
IL-1
inhibitors).Other
investigational
therapies
darunavir/cobicistat,
umifenovir,
sofosbuvir/daclatasvir,
sofobuvir/ledipasvir,
ribavirin,
nitazoxanide
interferon-based
regimens
not
evaluated
insufficient
data
efficacy
safety
these
agents.
Expert Review of Clinical Pharmacology,
Год журнала:
2022,
Номер
15(6), С. 759 - 766
Опубликована: Май 17, 2022
This
meta-analysis
of
randomized
controlled
trials
(RCTs)
investigated
the
clinical
efficacy
and
safety
favipiravir
for
patients
with
mild-to-critical
COVID-19.PubMed,
Web
Science,
Ovid
Medline,
Embase,
Cochrane
Central
Register
Controlled
Trials
were
searched
RCTs
published
before
30
October
2021.
Only
that
compared
-based
antiviral
regimens
(study
group)
other
alternative
treatments
or
placebos
(control
in
COVID-19
included.Overall,
improvement
rate
was
significantly
higher
study
group
than
control
at
assessment
conducted
after
14
days
(OR,
1.83;
95%
CI,
1.12-2.98).
The
virological
eradication
28
2.09;
1.15-3.78).
No
significant
difference
observed
rates
invasive
mechanical
ventilation
requirement
ICU
admission,
mortality,
risk
an
adverse
event
between
groups.Except
within
days,
favipiravir-based
treatment
did
not
provide
additional
benefit
COVID-19.
Therefore,
more
evidence
is
necessary.
PLoS ONE,
Год журнала:
2023,
Номер
18(7), С. e0288350 - e0288350
Опубликована: Июль 14, 2023
Coronavirus
disease
of
2019
(COVID-19)
is
a
global
health
problem.
The
impact
chronic
liver
diseases
on
the
course
and
outcome
COVID-19
still
subject
research.
aim
this
study
was
to
show
characteristics
patients
with
diseases,
establish
risk
factors
for
unfavourable
outcome.
Abstract
Background
The
Coronavirus
Disease
of
2019
(COVID-19)
pandemic
motivated
research
efforts
to
address
this
catastrophe
from
the
beginning
2020
present.
year
2021
is
coming
an
end,
and
several
developments
in
pharmacotherapy
for
COVID-19
have
occurred.
In
terms
antiviral
therapy,
monoclonal
antibody
combinations
become
one
type
immunotherapy.
Remdesivir
favipiravir
are
two
medications
typically
used
treat
COVID-19.
Paxlovid
(nirmatrelvir
plus
ritonavir)
molnupiravir
other
agents
purpose
study
was
compare
effects
antibodies
(casirivimab
imdevimab),
remdesivir,
on
swab
results
hospitalized
patients
with
at
discharge.
Methods
This
a
phase
IV
non-randomized
controlled
trial
(<
300
as
sample
size)
no
comparison
placebo.
study,
265
confirmed
by
polymerase
chain
reaction
(PCR)
indications
medication
were
into
three
groups
ratio
(1:2:2):
REGN3048-3051
(group
A),
remdesivir
B),
C).
A
nonrandomized
single-blind
design
used.
study's
provided
Hospital
Mansoura
University.
Following
ethical
approval,
conducted
approximately
6
months.
Results
Compared
favipiravir,
casirivimab
imdevimab
cause
less
hepatotoxicity,
renal
impairment,
more
negative
tested
antivirals
also
had
significant
adverse
effects.
All
considered
safe
based
these
findings.
Conclusion
result
better
clinical
outcomes.
toxicity.
Trial
registration
:
Clinicaltrials.gov,
NCT05502081,
16/08/2022.
